NEOHealthcare · Diagnostics & ResearchThe 11 Wall Street analysts covering NeoGenomics, Inc. hold a median 12-month price target of $22 — +28.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 4 Nov 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores NeoGenomics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (95): The shares have been drifting up relative to others.
Value (31): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NEO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +28.3% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Oct 2026 | BTIG | Reiterates | Buy | $28 |
| 29 Oct 2026 | TD Cowen | Maintains | Buy | $19 → $23 |
| 6 Oct 2026 | BTIG | Upgrade | Buy | $28 |
| 6 Oct 2026 | BTIG | Upgrade | Buy | — |
| 6 Oct 2026 | Needham | Maintains | Buy | $19 → $22 |
| 6 Oct 2026 | Needham | Maintains | Buy | — |
| 6 Oct 2026 | StoneX | Maintains | Buy | $16 → $20 |
| 6 Oct 2026 | StoneX | Maintains | Buy | — |
| 29 July 2026 | Needham | Maintains | Buy | — |
| 29 July 2026 | Needham | Maintains | Buy | $15 → $19 |
| 24 July 2026 | Benchmark | Maintains | Buy | $11 → $16 |
| 24 July 2026 | Benchmark | Maintains | Buy | — |
| 29 Apr 2026 | Benchmark | Upgrade | Buy | $11 |
| 29 Apr 2026 | Benchmark | Upgrade | Buy | — |
| 29 Apr 2026 | Leerink Partners | Upgrade | Outperform | — |
| 29 Apr 2026 | Leerink Partners | Upgrade | Outperform | $12 → $25 |
| 29 Apr 2026 | TD Cowen | Maintains | Buy | — |
| 29 Apr 2026 | TD Cowen | Maintains | Buy | $13 → $14 |
| 24 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Feb 2026 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NEO appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, NeoGenomics, Inc. returned +69.8% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 42% of US stocks
Cheaper than 33% of US stocks
Cheaper than 2% of US stocks
Higher than 56% of US stocks
Higher than 50% of US stocks
Higher than 56% of US stocks
Higher than 28% of US stocks
Higher than 25% of US stocks
Higher than 40% of US stocks
Higher than 37% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NeoGenomics, Inc. has a market value of $2.1B and an enterprise value of $2.4B.
Revenue in the twelve months to 30 June 2026: $766.3M. The latest quarter grew 11.4% year on year.
Net income over the same four quarters: −$51.9M, a −6.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.40.
Free cash flow in the twelve months to 30 June 2026: −$7.4M.
Trailing P/E: −20.4×; forward P/E: 54.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
NeoGenomics, Inc. employs 2,500 people — $307K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own NeoGenomics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
NeoGenomics reported third-quarter revenue growth of 11% year over year, led by continued expansion in next-generation sequencing testing. The company also raised its full-year revenue and adjusted EBITDA guidance.
Why it matters — The results and higher guidance offer NEO watchers an update on revenue growth and the company's full-year outlook.
NeoGenomics reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.06. Earnings were $0.03 per share in the year-ago quarter.
Why it matters — The earnings beat and year-over-year increase are relevant to NEO watchers assessing the company’s quarterly results.
NeoGenomics announced its third-quarter results for the period ended September 30, 2026.
Why it matters — The announcement concerns the company’s quarterly performance, which is relevant to NEO watchers, but the excerpt provides no results details.
NeoGenomics expanded its partnership with Indica Labs to scale AI-powered digital pathology. The effort is intended to support more timely and consistent diagnostic insights.
Why it matters — The expanded partnership relates to scaling digital pathology capabilities at NeoGenomics.
NeoGenomics announced that it will report its third quarter 2026 financial results after the close of U.S. financial markets on Wednesday, October 28, 2026.
Why it matters — NEO watchers may note the scheduled date for the company's third-quarter results.
The 11 Wall Street analysts covering NeoGenomics, Inc. have a median 12-month price target of $22, with estimates ranging from $19 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering NeoGenomics, Inc., 8 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeoGenomics, Inc. 70 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, NeoGenomics, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +28.3% from the last close, and Ticker Nerd's factor model ranks NeoGenomics, Inc. 70 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering NeoGenomics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NEO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $35 over the next 12 months.
NeoGenomics, Inc. returned +69.8% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
NeoGenomics, Inc. is a cancer diagnostics company focused on oncology testing and information services.
The most recent item we track (MarketBeat, 29 Oct 2026): "What NeoGenomics (NEO) Said on Its Q3 Earnings Call". NeoGenomics reported third-quarter revenue growth of 11% year over year, led by continued expansion in next-generation sequencing testing. The company also raised its full-year revenue and adjusted EBITDA guidance.
NeoGenomics, Inc. is a cancer diagnostics company focused on oncology testing and information services. The company provides a broad menu of laboratory solutions across the cancer care continuum, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, and pathology support. Its services are used by oncologists, pathologists, hospitals, academic medical centers, and pharmaceutical companies to help characterize disease, guide treatment decisions, and support clinical research and drug development. NeoGenomics operates a network of cancer-focused laboratories in the United States and the United Kingdom, with business operations organized around Clinical Services and Advanced Diagnostics. Headquartered in Fort Myers, Florida, NeoGenomics plays a specialized role in precision medicine by delivering laboratory data and expert interpretation for cancer diagnosis and care.
CEO Mr. Anthony P. Zook · 2,500 employees · United States · https://www.neogenomics.com
